Calamos Advisors
LBRX

Calamos Advisors’s LB Pharmaceuticals LBRX Stock Holding History

Calamos Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$623K Sell
19,198
-4,865
-20% -$143K ﹤0.01% 812
2026
Q1 		$593K Buy
+24,063
New +$555K ﹤0.01% 883

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Calamos Advisors's LBRX Position: Q2 2026 in Review

Calamos Advisors reduced its LB Pharmaceuticals (LBRX) stake by 20% in Q2 2026, selling an estimated $143K and leaving 19,198 shares worth $623K. The position accounts for ﹤0.01% of the portfolio, ranked #812.

Calamos Advisors first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Calamos Advisors held 19,198 shares of LB Pharmaceuticals worth $623K as of Q2 2026.
  • Calamos Advisors sold 4,865 LB Pharmaceuticals shares in Q2 2026, an estimated $143K.
  • LB Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #812 holding.
  • Calamos Advisors first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.